XKRX053030
Market cap366mUSD
Dec 26, Last price
17,380.00KRW
1D
-1.25%
1Q
-27.28%
Jan 2017
2.54%
Name
Binex Co Ltd
Chart & Performance
P/E
115.07
P/S
3.47
EPS
151.04
Div Yield, %
0.00%
Shrs. gr., 5y
0.89%
Rev. gr., 5y
8.27%
Revenues
154.82b
-1.18%
Net income
4.67b
-62.47%
CFO
3.78b
-77.86%
Dividend
Dec 29, 2008200 KRW/sh
Earnings
Mar 13, 2025
Profile
BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; vitamins and nutrients; antihistamine products; antivertigo products; and OTC products. BINEX Co., Ltd. has a co-development partnership with Genexine, Inc. to develop COVID-19 vaccine. The company was founded in 1957 and is based in Incheon, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 154,824,776 -1.18% | 156,677,024 16.58% | 134,399,279 1.07% | ||||||
Cost of revenue | 153,285,038 | 126,125,354 | 109,260,125 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 1,539,737 | 30,551,670 | 25,139,155 | ||||||
NOPBT Margin | 0.99% | 19.50% | 18.70% | ||||||
Operating Taxes | 311,129 | 2,868,264 | 5,203,654 | ||||||
Tax Rate | 20.21% | 9.39% | 20.70% | ||||||
NOPAT | 1,228,608 | 27,683,406 | 19,935,501 | ||||||
Net income | 4,670,748 -62.47% | 12,444,530 -34.83% | 19,094,152 197.78% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (12,000,000) | (5,324,411) | |||||||
BB yield | 4.13% | 1.13% | |||||||
| Debt | |||||||||
Debt current | 47,928,780 | 54,619,479 | 5,199,144 | ||||||
Long-term debt | 12,332,550 | 3,065,087 | 45,252,071 | ||||||
Deferred revenue | 1,688,555 | ||||||||
Other long-term liabilities | 754,767 | 1,257,563 | 6,913,587 | ||||||
Net debt | 16,378,763 | (29,370,108) | (55,348,976) | ||||||
| Cash flow | |||||||||
Cash from operating activities | 3,777,777 | 17,062,098 | 26,574,624 | ||||||
CAPEX | (7,747,267) | (36,453,163) | (19,793,182) | ||||||
Cash from investing activities | (14,179,951) | (39,124,800) | (13,804,185) | ||||||
Cash from financing activities | (12,573,199) | 3,223,216 | (13,318,606) | ||||||
FCF | (19,765,928) | 7,273,392 | 22,381,476 | ||||||
| Balance | |||||||||
Cash | 13,453,694 | 38,203,107 | 53,474,268 | ||||||
Long term investments | 30,428,873 | 48,851,566 | 52,325,923 | ||||||
Excess cash | 36,141,328 | 79,220,822 | 99,080,227 | ||||||
Stockholders' equity | 62,598,481 | 63,525,945 | 52,417,468 | ||||||
Invested Capital | 199,445,975 | 182,968,319 | 185,369,504 | ||||||
ROIC | 0.64% | 15.03% | 10.06% | ||||||
ROCE | 0.65% | 12.14% | 10.29% | ||||||
| EV | |||||||||
Common stock shares outstanding | 32,497 | 30,925 | 31,109 | ||||||
Price | 8,950.00 -22.51% | 11,550.00 -24.01% | 15,200.00 -42.75% | ||||||
Market cap | 290,845,751 -18.57% | 357,178,391 -24.46% | 472,856,861 -42.90% | ||||||
EV | 317,272,276 | 328,485,409 | 418,264,161 | ||||||
EBITDA | 10,520,412 | 38,852,585 | 31,143,314 | ||||||
EV/EBITDA | 30.16 | 8.45 | 13.43 | ||||||
Interest | 2,061,625 | 1,691,380 | |||||||
Interest/NOPBT | 6.75% | 6.73% | |||||||